Psoriasis in Children and Adolescents: Epidemiological Study of 280 Patients from Mexico

Andrea Tovar-Garza, Mayela Meza-Resendiz, Elizabeth Guevara-Gutiérrez, Juan Gabriel Barrientos-García and Alberto Tlacuilo-Parra

1Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas, USA; 2Instituto Dermatológico de Jalisco “Dr. José Barba Rubio”, Jalisco Ministry of Health, Zapopan, Jal.; 3UMAE Hospital de Pediatría, Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Jal. Mexico

ABSTRACT

Background: Psoriasis in children and adolescents has not been well studied in Mexico. Objective: To study the epidemiological characteristics of psoriasis in this age group. Methods: This is a retrospective study in an academic, tertiary care dermatology center from January 1999 to December 2014. We included patients ≤ 18 years of age, with clinical and histopathological diagnosis of psoriasis. We recorded the following information: gender, age, disease duration, clinical variant, nail involvement, treatment, and family history. Descriptive and inferential statistics were used for analysis. Results: Of 2,491 patients with psoriasis, 280 were ≤ 18 years of age, resulting in a prevalence of 11%. There was female predominance and the mean age was 11.5 years. Disease duration was 18 ± 34 months. Plaque psoriasis was the most common form, comprising 191 cases (68%). Nail involvement occurred in only 15 patients (5%). Topical treatment was given to 177 patients (63%). Only 14 cases (5%) had a family history of psoriasis. These variables did not differ when children were compared with adolescents, except in those with a shorter disease duration (13 ± 19 vs. 24 ± 29 months; p = 0.0004). Conclusions: We found a higher prevalence of psoriasis than previously published studies in this age group and a lower frequency of nail involvement and family history of psoriasis.

(intervet Clin. 2017;69:47-50)

Key words: Adolescent. Children. Epidemiology. Pediatric dermatology. Psoriasis.

INTRODUCTION

Psoriasis is a chronic inflammatory disease of the skin that affects 2-3% of the global population. Among children and adolescents, the prevalence depends on the population studied. In Germany the prevalence is 0.4%, whereas in India it is 12.5%. The prevalence also increases with age, being lower in patients one year old (0.12%), but much more common at 18 years of age (1.2%). Despite the frequency of psoriasis, epidemiological studies in this age group are scarce and there is no published data from Mexico. Our objective was to investigate the epidemiological characteristics of psoriasis in Mexican children and adolescents.
PATIENTS AND METHODS

We conducted a retrospective study between January 19, 1999 and December 31, 2014 at an academic, tertiary care dermatology center. We collected data from the medical charts and records of the histopathology department at the same center. We included Mexican patients (by birth), age ≤ 18 and with a clinical and histopathological diagnosis of psoriasis. Patients were classified as children (0-11 years) or adolescents (12-18 years). Recorded data included age, gender, disease duration, clinical variant, nail involvement, type of treatment, and family history of psoriasis. For data analysis, we used descriptive statistics such as the average and SD. For comparison of the qualitative variables, we used $\chi^2$ or Fisher’s exact test and for quantitative variables, Student’s t-test. Microsoft® Excel and the Epi-Info® statistical program were used for analysis.

RESULTS

During the 16-year period, we identified 2,491 patients with a clinical and histopathological diagnosis of psoriasis; 280 patients were ≤ 18 years old, corresponding to a prevalence of 11% in our institution. Of them, 242 (86%) came from the state of Jalisco, while the remaining 38 (14%) came from the states of Michoacán, Colima, Guanajuato, Zacatecas, Guerrero, Nayarit, Sinaloa, and Aguascalientes. Of the 280 cases, 133 (47%) were males and 167 (60%) were females, with a ratio of 1:1.5. The mean age at diagnosis was 11 ± 5 years (range, 7 months-18 years). The mean disease duration was 18 ± 34 months (range, 7 days-10 years). According to the psoriasis activity and severity index (PASI), a mild form (PASI 0-10) was reported in 193 (69%) patients and a moderate-to-severe form (PASI > 10) in 87 (31%). Overweight or obesity was detected in 118 (42%) patients.

The frequency of clinical variants is shown in table 1. The most common clinical variant was plaque psoriasis (68%). There were no cases of erythroderma. Nail involvement was present only in 15 cases (5%); nail matrix changes were the most common abnormalities (pitting 73%, onychauxis 13%, leukonychia 7%, and longitudinal grooves 7%). Fourteen patients (5%) had a family history of psoriasis, by first degree in eight (57%) and second degree in six (43%). Only two patients (0.7%) had comorbidities: one case of alopecia areata and one case of dermatomyositis.

Topical treatment as monotherapy was prescribed in 177 cases (63%), systemic in seven (2.5%), and a combination of both in 63 (22.5%) patients. Topical medications included keratolytics (salicylic acid or urea) in 94 cases (34%), coal tar or anthralin in 91 (32.5%), corticosteroids alone or combined in 89 (32%), vitamin D analogs alone or combined in 70 (25%), and calcineurin inhibitors in five (2%). Systemic medications were dapsone in 35 cases (12.5%), antibiotics in 31 (11%), and psoralens in five (2%).

A comparison of clinical variables in children and adolescents is shown in table 2. Plaque psoriasis was the most common type in both groups. Guttate psoriasis was more common in adolescents, whereas inverse psoriasis was more common in children (7%) compared to adolescents (2%), although it did not achieve statistical significance. Children had a shorter mean disease duration of 13 ± 19 months compared with teenagers (p = 0.0004).

DISCUSSION

The prevalence of psoriasis in Mexican children and adolescents (11%) was higher than that reported in Turkish (3.8%) and German (0.4%–0.71%) populations. In contrast, the frequency of a family history of psoriasis was lower (5%) compared to the Turkish study (23%). This difference could be explained mainly by the lack of awareness about the disease among family members of our patients and the retrospective nature of our study. Farber, et al. observed in their follow-up study that during subsequent consultations, patients reported a higher probability of family history. It...
Andrea Tovar-Garza, et al.: Psoriasis in Children and Adolescents

It is generally accepted that psoriasis is a phenotypically heterogeneous disease, resulting from an interaction with environmental factors and the activation of multiple genes in different kinds of cells, producing proinflammatory cytokines\textsuperscript{10-12}. It is also known that a family history of psoriasis is not always present.

In line with what has been reported in the literature, we also found a slight predominance of females, with a male:female ratio of 1:1.5, similar to studies from China (1:1.13)\textsuperscript{13}, Australia (1:1.14)\textsuperscript{14} and Germany (1:1.25)\textsuperscript{2}. The mean age at the time of diagnosis was lower than that reported in German patients (11 vs. 15 years)\textsuperscript{4}.

Plaque psoriasis was the most common variant in our study, similar to the German and Turkish studies, although they reported a lower frequency of 46.3–54.1\%\textsuperscript{2,8}. Guttate psoriasis has been reported as the most common variant in this age group\textsuperscript{15}; however, it was second to plaque psoriasis in our study. Inverse psoriasis had been noted more often in pre-pubertal children in a Swedish study, and we observed the same results\textsuperscript{15}. Nail involvement was not high in our study (5\%), similar to that reported in China (5.6\%); other authors report an 11–39\% prevalence, although there is good agreement that pitting is the most common finding\textsuperscript{3,16,17}.

With respect to treatment, previous reports have mentioned topical therapy as the first choice. However, there are no standardized guidelines on the treatment of psoriasis in children or adolescents, and randomized and controlled studies are scarce\textsuperscript{18}. In our institution, although the most frequently used treatment was also topical, corticosteroids were not the most frequent medications. Corticosteroids were prescribed in only 32\% of our patients, in contrast with their use in the majority of children in Germany (72.2\%)\textsuperscript{2} and Turkey (92\%)\textsuperscript{9}. The off-label use of dapsone is due to its anti-inflammatory and immunomodulatory effects; it has merely been employed in case series of psoriasis, with a good response\textsuperscript{19}. The use of systemic antibiotics was proportional with the number of patients with guttate psoriasis, likely due to the induction or exacerbation of psoriatic lesions by bacterial toxins\textsuperscript{20,21}.

We did not find differences between children and adolescents, except for disease duration, which allows us to infer that the behavior of psoriasis was similar in both age groups. Some of our variables are similar to previous studies, as shown in table 3. However, the age groups vary between studies and future, more comprehensive studies are required to allow for better comparisons.

To our knowledge, this is the first epidemiological study of psoriasis in children and adolescents done in Mexico. Limitations of our study include the retrospective nature of the study and ascertainment bias since only children referred to our tertiary care center were included.

Table 2. Comparison of children and adolescents with psoriasis (n = 280)

<table>
<thead>
<tr>
<th>Variable</th>
<th>Children (n = 132)</th>
<th>Adolescents (n = 148)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female</td>
<td>80 (61.0)</td>
<td>87 (59.0)</td>
<td>0.73*</td>
</tr>
<tr>
<td>Mean age (years) ± SD</td>
<td>7 ± 3</td>
<td>15 ± 2</td>
<td>0.0004*</td>
</tr>
<tr>
<td>Mean disease duration (months) ± SD</td>
<td>13 ± 19</td>
<td>24 ± 29</td>
<td>0.0004*</td>
</tr>
<tr>
<td>Plaque psoriasis (n = 191)</td>
<td>89 (67.0)</td>
<td>102 (69.0)</td>
<td>0.82*</td>
</tr>
<tr>
<td>Guttate psoriasis (n = 35)</td>
<td>16 (12.0)</td>
<td>19 (13.0)</td>
<td>0.72*</td>
</tr>
<tr>
<td>Palmar-plantar psoriasis (n = 32)</td>
<td>15 (11.0)</td>
<td>17 (11.0)</td>
<td>0.98*</td>
</tr>
<tr>
<td>Inverse psoriasis (n = 12)</td>
<td>9 (7.0)</td>
<td>3 (2.0)</td>
<td>0.07*</td>
</tr>
<tr>
<td>Pustular psoriasis (n = 5)</td>
<td>2 (1.5)</td>
<td>3 (2.0)</td>
<td>0.68†</td>
</tr>
<tr>
<td>Ungual psoriasis (n = 4)</td>
<td>1 (0.7)</td>
<td>3 (2.0)</td>
<td>0.62†</td>
</tr>
<tr>
<td>Ostraceous psoriasis (n = 1)</td>
<td>1 (0.7)</td>
<td>0 (0)</td>
<td>0.47†</td>
</tr>
<tr>
<td>Nail involvement (n = 15)</td>
<td>6 (4.5)</td>
<td>9 (6.0)</td>
<td>0.59*</td>
</tr>
<tr>
<td>Family history (n = 14)</td>
<td>6 (4.5)</td>
<td>8 (5.0)</td>
<td>0.76*</td>
</tr>
<tr>
<td>Topical treatment (n = 177)</td>
<td>90 (68.0)</td>
<td>87 (59.0)</td>
<td>0.20*</td>
</tr>
<tr>
<td>Systemic treatment (n = 7)</td>
<td>1 (0.7)</td>
<td>6 (4.0)</td>
<td>0.12†</td>
</tr>
<tr>
<td>Combined treatment (n = 63)</td>
<td>29 (22.0)</td>
<td>34 (23.0)</td>
<td>0.99*</td>
</tr>
</tbody>
</table>

*χ² test; †Fisher’s exact test; Student’s t-test.
In conclusion, the prevalence of psoriasis in our institute was higher than reported in other countries, although the presence of nail involvement and a family history of psoriasis were lower. The clinical variants we found are similar to those observed in adults, and most patients were treated in a conservative manner with topical medication.

ACKNOWLEDGEMENTS

We would like to thank Dr. Amit G. Pandya, University of Texas Southwestern Medical Center, Dallas, Texas, for reviewing and editing of the manuscript.

REFERENCES


